Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and   prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated   patients (pts) with metastatic castrate resistant prostate cancer   (mCRPC).

Document type:: Meeting Abstract
Author(s):: Massard, Christophe; Retz, Margitta; Hammerer, Peter; Quevedo, Fernando; Fong, Peter C. C.; Berry, William R.; Gurney, Howard; Piulats, Josep M.; Joshua, Anthony; Linch, Mark David; Kolinsky, Michael; Romano, Emanuela; Sridhar, Srikala S.; Conter, Henry Jacob; Augustin, Marinela; Wu, Haiyan; Schloss, Charles; Poehlein, Christian Heinrich; Yu, Evan Y.
Title:: Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
Journal title abbreviation:: J Clin Oncol
Year:: 2019
Journal volume:: 37 Suppl S
Journal issue:: 7
Fulltext / DOI:: doi:10.1200/JCO.2019.37.7_suppl.170
Print-ISSN:: 0732-183X
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: